News

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Robert Osher, MD, sat down with David Hutton of Ophthalmology Times to discuss the Lifetime Achievement award he received from the European Society of Cataract and Refractive Surgeons.

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.

American Academy of Ophthalmology offers in-person and virtual options for annual meeting, Subspecialty Day.

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been accepted as a late breaker at the 128th annual meeting of the American Academy of Ophthalmology, being held October 18-21 in Chicago.

Cutting-edge approaches for MDs and ODs

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

According to a team of researchers at the National Institutes of Health, their findings in animals suggest a surgery-free treatment for cataracts.

The new standard: Stabilizing keratoconus and improving vision.

IVW-1001 is a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, being developed to treat DED.

Unlocking the potential of donor scleral tissue: Innovations and future applications.

The report urges the US Department of Health and Human Services, in collaboration with departments of education at the state level, to take measures to ensure that children receive a vision screening before first grade and a comprehensive eye exam, when needed.

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, being held October 18 to 21 in Chicago, Illinois.

The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.

Option provides surgeons with flexibility and creativity.

German researchers found that their study results suggest that the effect of glaucoma on the elapsed time depends on disease progression. This uncertainty during everyday navigation tasks may adversely affect patients’ quality of life.

Prevent Blindness is offering free resources to help educate the public and allied healthcare professionals on the many types of inflammatory eye diseases, and steps that should be taken to prevent vision loss.

Researchers at the Karolinska Institute continue to investigate whether gene therapy can improve vision in people with Bothnia dystrophy, a form of hereditary blindness, prevalent in the region Västerbotten in Sweden.

Meeting in Stockholm provides education, updates, and a taste of culture.

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular degeneration at the Retina Society 57th Annual Scientific Meeting in Lisbon, Portugal.

Common glaucoma treatments may worsen ocular surface disease and meibomian gland dysfunction, leading to discomfort, redness, and even poor treatment compliance.

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 clinical trial results for ONL-1204 for rhegmatogenous retinal detachment from the Retina Society meeting being held this year in Lisbon, Portugal.

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the 12-month outcomes of the FARETINA and FARWIDE studies from the Retina Society meeting being held this year in Lisbon, Portugal.

According to the company, the pilot study showed procedural feasibility of ophthalmic artery angioplasty in the treatment of vascular lesions associated with geographic atrophy (GA).

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Visual acuity and macular anatomy were maintained, with some changes in fluid management.